Domino's Pizza Posts Revenue Gains on Increased Same-Store Sales
The pizza-restaurant chain reported a profit of $131.1 million, or $3.81 a share, compared with $142 million, or $4.03 a share in the year prior. Wall Street expected $3.95 a share.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Biotech Is Booming, and This Undervalued REIT Stands to Gain
While most commercial office landlords are still hunting for post‑pandemic tenants, there's a sector of the real estate industry that's breeding breakout growth: life sciences. Global biotech spending is projected to triple from roughly $1.7 trillion in 2025 to more than $5 trillion by 2034. All that R&D cash needs purpose‑built laboratory space. That's what makes Alexandria Real Estate Equities (NYSE: ARE) such a standout real estate investment trust (REIT). It owns the largest portfolio of labs and life-science properties in the United States and has a client base of approximately 750 high-quality tenants, including Eli Lilly, Moderna, and Bristol-Myers Squibb. With this strong tenant base, Alexandria is poised to generate returns that could replicate like stem cells. Tenants engineered for long-term occupancy With occupancy rates of 92% and the majority of their space leased to biotech, pharmaceutical, and agricultural technology (AgTech), Alexandria is in a league of its own in comparison to other REITs. Given the highly specialized nature of their business, laboratory tenants require customized spaces, so they sign longer leases and rarely move. Thanks to this, last quarter, ARE locked in rent increases of 18.5% on average when tenants renewed and 7.5% when new ones signed, a strong sign of pricing power even during a period of lower leasing demand. The company also has a weighted-average remaining lease term of 7.6 years, indicating strong tenant commitment and predictable long-term cash flow, boosting the company's overall income stability. With a lease portfolio this stable, you could call it genetically engineered for sizable returns. Rebuilding the balance sheet with surgical precision Instead of chasing growth for growth's sake, management has been smartly recycling capital. During 2024, it focused on selling noncore assets to free up cash, reduce debt exposure, and reinvest funds into higher-yielding developments, an approach that improves returns while lowering long-term risk. For 2025, it plans another $2 billion of dispositions and minority‑interest sales, roughly one third of which is already closed or under contract. Proceeds are being funneled into its high‑margin mega‑campus developments that have consistently proven profitable for ARE, further strengthening the company's financial position. Only 13 % of outstanding debt matures before 2028, and the average term is now over 12 years, which is longer than any other REIT in the S&P 500 (SNPINDEX: ^GSPC). Incubating tomorrow's rent roll Even with occupancy not at full capacity, Alexandria has roughly 4 million square feet of Class A lab projects under construction in Boston, San Diego, and the Bay Area. Much of that space is pre‑leased, and the rest should command premium rents once biotech funding rebounds. Combined with contractually built-in rent escalators that will boost revenue annually even without new leases, that pipeline points to rising cash flow in the near future. After paying dividends, the company still expects to retain roughly $475 million of operating cash this year, enough to self‑fund a good chunk of its expansion. Potential side effects to monitor Investors should keep in mind that, while the long-term outlook for the life sciences industry is favorable, demand can be cyclical. If the biotech funding window slams shut due to larger macroeconomic trends, leasing of ARE's new projects could slow. Rising interest rates are another wild card. Alexandria's current interest‑rate swaps shield it for now, but costs will climb when that protection rolls off. Additionally, biotech companies operate on long R&D cycles. If a wave of Alexandria's tenants hit clinical trial setbacks or fail to bring products to market, they may downsize or go out of business, reducing demand for space. Management already trimmed its 2025 adjusted funds from operations (AFFO) guidance after a small dip in occupancy and higher interest expense. As AFFO is a key metric used to assess a REIT's true operating performance and its ability to support dividends, any downward revision can signal slower growth or pressure on dividend safety if trends persist. The company also missed its Q1 2025 earnings per share (EPS) forecast, reporting a $0.07 loss per share versus the $0.76 expected. While EPS isn't as relevant as FFO for REITs, the miss still raised questions about timing of asset sales, operating expenses, and lease activity. Investors should watch closely to make sure management follows through on its efficiency and disposition goals in upcoming quarters. A prescription for income and upside Alexandria currently trades around $71 a share and yields a 7.27% dividend, far above the 4% average REIT payout. More importantly, last quarter's dividend used just 57% of FFO. That's considered a conservative payout ratio for a REIT, suggesting that the company isn't stretching itself to pay investors. ARE also appears to be extremely undervalued right now. It trades approximately 7x forward FFO, lower than many other high-quality REITs, especially those with stable tenants and strong growth prospects. Shares still trade more than 65% below their 2021 peak, meaning ARE offers both attractive yield today and potential upside tomorrow. For income seekers willing to stomach a bit of volatility, Alexandria Real Estate Equities looks like a REIT worth implanting into a diversified portfolio. Should you buy stock in Alexandria Real Estate Equities right now? Before you buy stock in Alexandria Real Estate Equities, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Alexandria Real Estate Equities wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 The Motley Fool has positions in and recommends Alexandria Real Estate Equities and Bristol Myers Squibb. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. Biotech Is Booming, and This Undervalued REIT Stands to Gain was originally published by The Motley Fool
Yahoo
23 minutes ago
- Yahoo
Cattle Closes with Gains, as Cattle on Feed Shows Fewer Placements
Live cattle futures posted gains of with 67 cents to $1.00 to close out the day, as August was up $2.92 this week. Cash activity settled in at $230-231 in the South this week, with $240-242 in the North. The Friday morning Fed Cattle Exchange online auction from Central Stockyards showed $237.50 sales on 325 head out of KS, with $233 TX BidTheGrid™ sales on 120 head. Feeder cattle futures closed the Friday session with contracts up $2.47 to $2.65, as August was $7.37 higher on the week. The CME Feeder Cattle Index was back up $2.65 to $328.83 on July 24. Cattle on Feed data showed June placements down 7.86% from last year at 1.411 million head and well below estimates. Marketings were 1.707 million head and 4.42% below June 2024. July 1 on feed was tallied at 11.195 million head, down 0.96% from a year ago. The bi-annual July Cattle Inventory report was released after a hiatus last year, with July 1 beef cow inventory down 1.2% from 2023 at 28.65 million head. Beef replacement heifers were 5.1% below 2023 at 3.7 million head. More News from Barchart Coffee Prices Settle Higher on Brazil Weather Risks Grain Market Update: Where are Soybean, Corn, and Wheat Prices Headed? Cocoa Prices Finish Sharply Lower as Chocolate Demand Wanes Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. June beef stocks were tallied at 395.678 million lbs according to Cold Storage data. That was a 2.98% decline from May and 0.92% below last year. USDA Wholesale Boxed Beef prices were back in the red in the Friday afternoon report, with the Chc/Sel spread at $21.85. Choice boxes were quoted $1.41 lower at $366.68, while Select was down $2.13 to $344.87. USDA estimated cattle slaughter for this week at 549,000 head. That was down 14,000 head from last week and 56,176 head lower vs. the same week in 2024. Aug 25 Live Cattle closed at $226.475, up $0.675, Oct 25 Live Cattle closed at $223.150, up $1.000, Dec 25 Live Cattle closed at $223.475, up $0.825, Aug 25 Feeder Cattle closed at $331.375, up $2.475, Sep 25 Feeder Cattle closed at $332.200, up $2.550, Oct 25 Feeder Cattle closed at $331.000, up $2.650, On the date of publication, Austin Schroeder did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on 登入存取你的投資組合
Bloomberg
25 minutes ago
- Bloomberg
US Cattle Tally Shows No End in Sight for Soaring Beef Prices
The latest US cattle tally offered little relief for consumers paying record beef prices, even as the cycle of herd liquidation seems to be coming to an end. There were about 94.2 million cattle and calves in the US as of July 1, the lowest mid-year count on record in data going back to 1973, the Department of Agriculture said in a report. The number of animals placed in feedlots for weight gain before being sent to slaughter plunged to the lowest since 2017, the USDA said in a separate note.
